Dr. Garon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2020 Santa Monica Blvd., 6th Floor
Santa Monica, CA 90404Phone+1 310-829-5471Fax+1 310-829-5471
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of ChicagoResidency, Internal Medicine, 1999 - 2002
Washington University in St. Louis School of MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2003 - 2026
IL State Medical License 1999 - 2005- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2004 Oct 28
- Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2009 Jan 01
- Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 01
- Join now to see all
Publications & Presentations
PubMed
- 4088 citationsPembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerLeena Gandhi, Delvys Rodriguez-Abreu, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip
The New England Journal of Medicine. 2018-04-16 - 376 citationsA Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLCAaron Lisberg, Amy L. Cummings, Jonathan W. Goldman, Krikor Bornazyan, Nicholas Dean Reese
Journal of Thoracic Oncology. 2017-11-01 - 227 citationsPemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNO...Delvys Rodriguez-Abreu, Steven Francis Powell, Maximilian Hochmair, Shirish M. Gadgeel, Emilio Esteban
Annals of Oncology. 2021-07-01
Journal Articles
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung CancerEdward B Garon, Maeve Waldron-Lynch, The New England Journal of Medicine
Lectures
- Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.2019 ASCO Annual Meeting - 6/1/2019
- Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Controversies, Difficult Questions Arise in NSCLC Amid New DataFebruary 2024
Press Mentions
Dr. Garon on Considerations Regarding the Use of Perioperative Immunotherapy in Lung CancerJuly 4th, 2024- High-Dose Radiotherapy with Chemotherapy Effective in Treating People with Non-Small Cell Lung CancerJanuary 11th, 2024
- How a Biomarker Test Saved This Lung Cancer Survivor’s LifeNovember 30th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
